BOULDER, Colo.--(BUSINESS WIRE)--Jul. 24, 2012--
Array BioPharma (NASDAQ: ARRY) announced today that it has appointed
Andrew Robbins to the position of Senior Vice President of Commercial
Operations. The creation of this new position reflects the Company’s
continued transformation towards a commercial-stage company, as several
products in the Array pipeline approach pivotal trials, including its
wholly owned myelodysplastic syndrome and multiple myeloma programs. In
his new role, Mr. Robbins will be responsible for working with Array’s
research and development teams to refine the Company’s strategy,
prioritizing portfolio investments and supporting corporate
collaborations with Array’s strategic partners. As Array’s products move
closer to market, he will develop launch plans and build an integrated
sales and marketing team.
Andrew Robbins, Senior Vice President, Commercial Operations, Array BioPharma (Photo: Business Wire)
"I am delighted that Andy has decided to join the Array team,” said Ron
Squarer, Chief Executive Officer. “I am confident his commercial
development expertise and strategic insight will contribute to Array’s
immediate and future successes."
Mr. Robbins has extensive commercial, development and strategic
leadership expertise from a 15-year career in the pharmaceutical
industry, with a specific focus on oncology/hematology products. Most
recently he was at Hospira, Inc. where he served as General Manager/Vice
President of the U.S. Alternate Site business unit, focused on the sales
of pharmaceuticals and medical devices to outpatient oncology, surgery,
pain and dialysis customers. In this role, he led a team of
approximately 100 employees, including a national sales force, to
deliver over $400 million in annual revenue. Prior to this, he was Vice
President of Corporate Development and was responsible for global
branded pharmaceutical marketing and business development, research and
development portfolio prioritization, global strategy and corporate
venture investing. During his tenure, he designed and executed a
strategy to build a late-stage hematology/oncology and acute pain
pipeline via licensing and acquisition. Mr. Robbins also served on the
Board of Directors for three venture-backed healthcare companies, two of
which were focused on innovative hematology/oncology products.
Before Hospira, Mr. Robbins was a commercial leader within Pfizer’s
oncology unit, responsible for shepherding a portfolio of 12 preclinical
and clinical stage products through development using a
“fast-to-patient” approach. Several of these products, including Sutent®
(sunitinib), Inlyta® (axitinib) and Xalkori® (crizotinib)
have been commercialized.
Mr. Robbins holds an MBA from the Kellogg School of Management,
Northwestern University and a bachelor's degree from Swarthmore College.
About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the
discovery, development and commercialization of targeted small-molecule
drugs to treat patients afflicted with cancer and inflammatory diseases.
Array has four core proprietary clinical programs: ARRY-614 for
myelodysplastic syndromes, ARRY-520 for multiple myeloma, ARRY-797 for
pain and ARRY-502 for asthma. In addition, Array has 10 partner-funded
clinical programs including two MEK inhibitors in Phase 2: selumetinib
with AstraZeneca and MEK162 with Novartis. For more information on
Array, please go to www.arraybiopharma.com.
Forward-Looking Statement
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995,
including statements about expectations that events will occur that will
result in greater value for the Company, the potential for the results
of ongoing preclinical and clinical trials to support regulatory
approval or the marketing success of a drug candidate, our future plans
to progress and develop our proprietary programs and the plans of our
collaborators to progress and develop programs we have licensed to them
and our plans to build a commercial-stage company. These statements
involve significant risks and uncertainties, including those discussed
in our most recent annual report filed on Form 10-K, in our quarterly
reports filed on Form 10-Q, and in other reports filed by Array with the
Securities and Exchange Commission. Because these statements reflect our
current expectations concerning future events, our actual results could
differ materially from those anticipated in these forward-looking
statements as a result of many factors. These factors include, but are
not limited to, our ability to continue to fund and successfully
progress internal research and development efforts and to create
effective, commercially viable drugs; risks associated with our
dependence on our collaborators for the clinical development and
commercialization of our out-licensed drug candidates; the ability of
our collaborators and of Array BioPharma Inc. to meet objectives tied to
milestones and royalties; our ability to effectively and timely conduct
clinical trials in light of increasing costs and difficulties in
locating appropriate trial sites and in enrolling patients who meet the
criteria for certain clinical trials; risks associated with our
dependence on third-party service providers to successfully conduct
clinical trials within and outside the United States; our ability to
achieve and maintain profitability and maintain sufficient cash
resources; the extent to which the pharmaceutical and biotechnology
industries are willing to in-license drug candidates for their product
pipelines and to collaborate with and fund third parties on their drug
discovery activities; our ability to out-license our proprietary
candidates on favorable terms; and our ability to attract and retain
experienced scientists and management. We are providing this information
as of July 24, 2012. We undertake no duty to update any forward-looking
statements to reflect the occurrence of events or circumstances after
the date of such statements or of anticipated or unanticipated events
that alter any assumptions underlying such statements.
Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50352085&lang=en
Source: Array BioPharma
Array BioPharma
Tricia Haugeto, 303-386-1193
thaugeto@arraybiopharma.com
